Axsome Therapeutics (AXSM.Q) announced today that its AXS-05 has met primary and key secondary endpoints in the MERIT (Mechanistic Evaluation of Response in TDR) Phase 2 trial. Additionally, the…
Search Results for: axsm.q
Eye Don’t Believe It Fill Disclosure: weekly roundups are intended to provide a quick introduction to various companies. They are not intended to be deep dives or opinion…
Nice Mice Considering the amount of junk food I have eaten in the past week, I figured now is as good a time as any to talk about…